Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Although clinical guidelines often recommend platinum-based TCHP, emerging evidence from trials like NEOCARP and Helena 06 shows that platinum-free THP yields comparable pathologic complete response rates. Dr. Nadine Tung explains that historically, platinum added minimal benefit over taxanes and dual-HER2 antibodies, making platinum omission an attractive de-escalation strategy for stage 2 patients to avoid unnecessary toxicities like neuropathy.

Related Insights

While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.

For lower-risk Stage 2/3 HER2+ breast cancer, clinicians can start with THP, assess response via MRI, and only then proceed to TDXD if necessary. This risk-stratified approach to the DESTINY-Breast11 regimen can spare some patients the unique toxicities of TDXD.

Real-world data shows that in platinum-sensitive ovarian cancer patients who have progressed on PARP inhibitors, subsequent platinum-based chemotherapy has a surprisingly low response rate of only 20%. This quantifies a significant opportunity for highly active ADCs to potentially replace platinum in this growing patient population.

The DESTINY-Breast11 trial showed a neoadjuvant regimen of TDXD followed by THP achieved a 67.3% pathologic complete response (pCR) rate in high-risk HER2+ breast cancer. This is the highest pCR rate seen in a registrational trial, signaling a potential new standard of care.

A subtle finding in the DESTINY-Breast11 trial, where TDXD alone underperformed TDXD followed by THP, suggests that taxane-based chemotherapy might remain effective even after a patient's HER2-positive cancer becomes resistant to the antibody-drug conjugate TDXD.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

The DESTINY-Breast11 trial demonstrated superior pCR rates using neoadjuvant T-DXd followed by THP, but Dr. Nadine Tung cautions against treating all patients with maximally intensive therapy. Because two-thirds of ER-negative patients already achieve pCR with just four cycles of THP, universal escalation causes overtreatment. Instead, clinicians should reserve intensive antibody-drug conjugate regimens for patients with high tumor burden or unfavorable biology.

The widely used TCHP chemotherapy regimen is weakening under scrutiny. Multiple randomized trials now show that adding carboplatin (the 'C') provides no additional benefit in shrinking tumors but increases toxicity, directly challenging its standing as a recommended standard of care in guidelines.

In the CompassHER2 analysis, anatomical factors like nodal involvement and T stage did not predict pathologic complete response, with the lone exception of T3 tumors in ER-negative disease. Dr. Nadine Tung highlights that biological factors—such as receptor expression and genomic signatures—drive chemosensitivity much more than anatomical tumor volume, suggesting clinicians should base de-escalation decisions primarily on biological characteristics.

A key debate in early HER2+ breast cancer is whether to use TDXD neoadjuvantly (DESTINY-Breast11) or reserve it for post-op residual disease (DESTINY-Breast05). Many experts favor the neoadjuvant approach to maximize the chance of a pathologic complete response (pCR), which allows for surgical de-escalation and is associated with better outcomes.